glp-1 for obesity Frontiers CMS Issues Coverage Guidance on

These medications go beyond lowering blood glucose they also help protect the heart and kidneys, and in some cases, promote weight loss

10.1016/j.biopha.2021.112515 176 Van SkikeC

About CT-996 study 6 The CT-996-201 trial (NCT05814107) is a multi-part, multi-cohort Phase I randomised, double-blind, placebo-controlled, single- and multiple- ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CT-996 in otherwise-healthy adults who are overweight or obese, with and without type 2 diabetes

Q3: Which medication is preferred for managing diabetes in pregnant patients